Zimmermann, T., Heinrichs, N., & Baucom, D.H. (2007). “Does one size fit all?” Moderators in psychosocial interventions for breast cancer patients: A meta-analysis. Annals of Behavioral Medicine, 34, 225–239.
To illuminate the moderators of the effect of psychosocial interventions and better understand the variability of these effects in patients with cancer; to test the hypothesis that cancer type, intervention type, and interventionist can moderate intervention effect
Initially, investigators retrieved 127 articles, of which 46 were eliminated because they did not report on RCTs. Four of the 127 articles were unavailable. Of the remaining 77 reports of RCTs, the data in 26 were incomplete. Communication with the authors of studies with incomplete data resulted in obtaining complete data for five studies.
Nurses are particularly suited to providing psychoeducational and educational interventions for patients, and these types of nurse-led interventions can have a positive effect on patient outcomes. Psychologist-delivered CBT interventions seem to be more effective than nurse-delivered CBT interventions. This finding suggests that, if nurses are to provide CBT, the nurses must develop significant expertise.This finding may also suggest the importance of interdisciplinary approaches to providing psychosocial interventions. This meta-analysis demonstrated that moderators have a significant effect on intervention effectiveness; therefore, future studies should provide information about potential moderators.
Zimmerman, C., Atherton, P.J., Pachman, D., Seisler, D., Wagner-Johnston, N., Dakhil, S., . . . Loprinzi, C.L. (2016). MC11C4: A pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in Cancer, 24, 1071–1078.
To obtain data to support conducting a phase III trial of venlafaxine to prevent oxaliplatin-induced neurotoxicity
Patients were stratified according to planned calcium and magnesium administration, cancer stage, and treatment cycle, then randomized to receive venlafaxine extended release 37.5 mg versus placebo twice daily. The study treatment was begun on the evening of the first or second chemotherapy treatment and continued for one week following completion of the FOLFOX treatment. Assessments were taken at baseline, prior to each FOLFOX treatment, and at 1, 3, 6, and 12 months postcompletion.
PHASE OF CARE: Active antitumor treatment
Randomized, double-blind, placebo-controlled trial
No significant differences in any measures of neuropathy outcomes existed between groups.
Venlafaxine did not reduce neuropathic toxicities associated with oxaliplatin.
Small sample (< 100)
Data from this trial do not support the use of venlafaxine for the prevention of neuropathic symptoms associated with oxaliplatin. Ongoing research is needed to identify effective interventions for this treatment complication.
Zimmermann, A., Wozniewski, M., Szklarska, A., Lipowicz, A., & Szuba, A. (2012). Efficacy of manual lymphatic drainage in preventing secondary lymphedema after breast cancer surgery. Lymphology, 45(3), 103–112.
To evaluate effectiveness of manual lymphatic drainage (MLD) for prevention of secondary lymphedema after breast cancer surgery
From the second post-operative day, women received a standard program of exercises. Thirty-three women were randomly chosen to also receive MLD five times a week for the first two weeks, then twice a week until six months after surgery. The other control group women applied self-drainage. Data were collected prior to surgery and at six months postoperatively. Arm volume measurements were done on days 2, 7, 14, and 3 and 6 months.
The study took place at a single outpatient site in Poland.
The patients were undergoing multiple phases of care.
The study used a prospective trial design.
Water displacement was used to measure arm volume.
Women in the MLD group showed a reduction of 14 ml volume (SD = 470 ml) on the operated-side arm over six months. Women in the control group showed an overall increase in arm volume of 16 ml (SD = 470, p = 0.0033). Analysis of variance showed significant effect of having MLD (p = 0001) and radiotherapy (p = 0.0499) on arm volume.
Findings showed that use of MLD may have some benefit for prevention of lymphedema secondary to breast cancer surgery. Several study limitations suggest that findings should be used with caution.
Findings of the study do not provide strong support for effectiveness of MLD to prevention lymphedema after breast surgery because of the multiple study design and results limitations.
Zielinski, J., Jaworski, R., Smietanska, I., Irga, N., Wujtewicz, M., & Jaskiewicz, J. (2011). A randomized, double-blind, placebo-controlled trial of preemptive analgesia with bupivacaine in patients undergoing mastectomy for carcinoma of the breast. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 17(10), CR589–597.
To test the effect of bupivacaine, applied in the area of surgical incision, on the pain experienced by postmastectomy patients; to see how the bupivacaine affected use of analgesics
Before mastectomy, women were randomized to receive bupivacaine application or saline placebo. The bupivacaine group received 100 mg bupivacainum hydrochloricum dissolved in normal saline. The control group received normal saline. Bupivacaine and saline were administered in the same way: subcutaneously, along the intended line of incision, 15 minutes before the operation. All patients received standard oral premedication: 7.5 mg midazolam. Anesthesia consisted of propofol, 2 mg/kg body weight; vecuronium, 0.6 mg/kg; and fentanyl, 2 mcg/kg. After surgery, each patient had the option of patient-controlled analgesia, which consisted of standard drug concentrations based on body weight. IV metamizole, 1g, was administered every 6 hours. Pain was measured at 1, 2, 3, 4, 8, 12, 16, 20, 24, 36, and 48 hours postoperatively. Total analgesic consumption was recorded.
Active treatment
Randomized double-blind placebo-controlled trial
Visual analog scale (VAS), with a 0–10 scale, to measure pain severity
Compared to patients receiving placebo, patients receiving bupivacaine reported significantly lower pain severity at the 4th (p = 0.004) and 12th p = 0.02) postoperative hours. Patients receiving bupivacaine used less fentanyl (p = 0.011). Between the 4th and 12th postoperative hours, those receiving bupivacaine used less PCA morphine (p = 0.02) than did the control group. The pattern of VAS scores was similar in both groups, with a spike in pain during the first postoperative hour and a gradual decline thereafter. Across the first 12 hours, pain scores in the bupivacaine group were consistently lower than the scores in the control group. Authors noted no differences between groups in regard to time to first morphine dose or total amount of morphine used during the postoperative follow-up.
Preoperative subcutaneous injection of bupivacaine to the site of surgical incision was effective in reducing patients' pain severity and morphine consumption during the first 12 hours after mastectomy.
Findings provide support for the use of bupivacaine injection to relieve postmastectomy pain. Nurses can advocate for consideration of this approach as part of surgical pain management. Note that these results are not immediately generalizable to other surgical populations.
Zidan, J., Haim, N., Beny, A., Stein, M., Gez, E., & Kuten, A. (2001). Octreotide in the treatment of severe chemotherapy-induced diarrhea. Annals of Oncology, 12(2), 227–229.
Patients with chemotherapy-induced diarrhea (CID) refractory to loperamide received 100 mcg subcutaneous octreotide three times per day for three days followed by 50 mcg three times per day for three days. The median time between chemotherapy and starting octreotide was 8 days (range = 5–9 days).
This was a prospective study.
Patients recorded the number of bowel movements. Complete response (CR) was defined as no diarrheal stools per day; partial response (PR) was defined as 1–2 diarrheal stools per day; and no response was defined as three or more diarrheal stools per day. Progression was defined as an increase in the number of diarrheal stools.
Octreotide was found to be highly effective as second-line therapy in managing patients with CID.
The sample size was small.
Zick, S.M., Sen, A., Wyatt, G.K., Murphy, S.L., Arnedt, J.T., & Harris, R.E. (2016). Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: A randomized clinical trial. JAMA Oncology, 2, 1470–1476.
To identify improvement in fatigue, sleep, and quality of life in breast cancer survivors using self-administered acupressure
Self-administered relaxing acupressure or stimulating acupressure performed once daily for three minutes for six weeks. Assessments were conducted at baseline, three weeks (to assess technique), six weeks (end of intervention), and 10 weeks (washout).
Self-administered relaxing and stimulating acupressure may improve fatigue in breast cancer survivors who have completed treatment at least 12 months ago. Relaxing acupressure may also improve sleep and quality of life in this patient group.
Self-administered relaxing and stimulating acupressure may be beneficial in the reduction of fatigue in breast cancer survivors who have completed treatment at least 12 months ago. Additional studies could be conducted with those currently receiving treatment and with patients with other cancers.
Zick, S.M., Ruffin, M.T., Lee, J., Normolle, D.P., Siden, R., Alrawi, S., & Brenner, D.E. (2009). Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Supportive Care in Cancer, 17, 563–572.
To evaluate the efficacy of ginger in relief of delayed chemotherapy-induced nausea and vomiting (CINV)
Patients with cancer who had experienced CINV during at least one previous round of chemotherapy were asked to participate. All participants were receiving a 5-HT3 receptor antagonist or aprepitant as part of their standard antiemetic regimen. Patients were randomized to receive either 1.0 g of ginger, 2.0 g of ginger, or matching placebo daily for three days.
The study was conducted at multiple outpatient settings in Ann Arbor, MI.
All patients were in active treatment.
This was a randomized double-blind, placebo-controlled trial.
The Morrow Assessment of Nausea and Emesis (MANE) and the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 for Adverse Events were used.
Ginger extract provides no clinical benefit at the doses evaluated when given in addition to standard, evidence-based medical therapy to prevent CINV. Ginger extract may have a negative effect on severity of nausea when taken with aprepitant.
Ziakas, P.D., Kourbeti, I.S., Voulgarelis, M., & Mylonakis, E. (2010). Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clinical Therapeutics, 32, 2316–2336.
To estimate the impact of antifungal prophylaxis on the occurrence of proven systemic fungal infections in patients with neutropenia and to quantify its effect on mortality attributed to these infections.
Databases searched were MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through September 15, 2010. In addition, proceedings of the annual meetings of the Infectious Diseases Society of America (2001–2009), the American Society of Hematology (2000–2009), and the European Society of Clinical Microbiology and Infectious Diseases (2000–2010) were manually reviewed.
Search keywords were clinical trial(s), neutropenia, neoplasms, malignant, malignant neoplasm, mycoses, candida, aspergillus, zygomycosis, antifungal agents/antifungal, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, miconazole, and micafungin.
Articles were included if they focused on patients undergoing treatment for cancer who received prophylactic antifungal medications.
Articles were excluded if they directly compared systemic antifungal prophylactic agents, evaluated nonabsorbable polyenes or oral antifungal formulations of amphotericin B, and did not evaluate antifungals prophylactically (i.e., those that included empirical, pre-emptive, or salvage therapies for fungal mycoses).
A total of 11,418 references were retrieved.
A meta-analysis method of study was used. In specific, statistical analysis was performed to compare study results, including effects of antifungal prophylaxis using random effects and reported as pooled odds ratios (ORs) and 95% confidence intervals (CIs) using the Robins-Breslow-Greenland formula. For study cells with zero events, an ad hoc treatment arm continuity correction was used. Findings in which the 95% CI crossed 1 were not considered statistically significant. Statistical heterogeneity was assessed using the I2 statistic and Cochrane Q test. The Petro method was used for sensitivity analysis, and the Harbord modification of the Egger test was used to evaluate small study effects for major outcomes.
Patients were undergoing the active treatment phase of care.
Antifungal prophylaxis was associated with statistically significant reductions in proven fungal infections (OR = 0.43; 95% CI [0.31, 0.6]; number needed to treat [NNT] = 20) and mortality attributed to fungal infections (OR = 0.49; 95% CI [0.3, 0.8]; NNT = 53), reduction in risk for proven candida infections (OR = 0.28; 95% CI [0.2, 0.38]), and a decreased need for antifungal therapy (OR = 0.64; 95% CI [0.48, 0.86]). Explanatory subanalysis of major outcomes showed a reduced risk for proven infections among HSCT recipients only (OR = 0.27; 95% CI [0.16, 0.44]) and infection-related mortality (OR = 0.41; 95% CI [0.21, 0.81]). Not statistically significant were overall mortality (OR = 0.92; 95% CI [0.74, 1.14]) or reduction of aspergillosis or zygomycosis. Meta-regression analysis showed that multi-center and double-blind designs were significant moderators of the effect of antifungal prophylaxis on overall mortality and proven systemic fungal infections.
Systemic antifungal prophylaxis was associated with decreased proven fungal infections and fungal infection-related mortality in patients with neutropenia following chemotherapy. Antifungal prophylaxis was also associated with decreased proven infections and infection-related mortality in HSCT recipients. Overall mortality was not improved through the use of antifungal prophylactic therapy.
The use of prophylactic antifungal therapy should be considered for patients receiving neutropenic-inducing chemotherapy and/or those undergoing HSCT.
Zhu, G., Lin, J.C., Kim, S.B., Bernier, J., Agarwal, J.P., Vermorken, J.B., . . . He, X. (2016). Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer, 16, 42-016-2073-z.
RESOURCE TYPE: Consensus-based guideline
PROCESS OF DEVELOPMENT: Asian expert panel of head and neck cancer specialists
PHASE OF CARE: Active treatment
This review and expert opinion were limited to patients with head and neck squamous cell carcinoma undergoing radiation therapy with or without cetuximab or chemotherapy. The authors’ proposal of a new grading system was noted to be adapted from the authors who previously addressed the need for a new grading system.
Zhu, M., Liang, R., Pan, L.H., Huang, B., Qian, W., Zhong, J.H., . . . Li, C.L. (2013). Zoledronate for metastatic bone disease and pain: A meta-analysis of randomized clinical trials. Pain Medicine, 14, 257–264.
STUDY PURPOSE: To determine the efficacy and safety of zoledronate in treating pain related to metastatic bone disease
TYPE OF STUDY: Meta-analysis and systematic review
DATABASES USED: PubMed, EMBASE, and the Cochrane Library up to October 2011
KEYWORDS: Zoledronic acid and bone metastasis, and these two terms in combination with zoledronate and bone pain
INCLUSION CRITERIA: Patient had at least one site of bone metastasis; Eastern Cooperative Oncology Group performance status of 2 or less; the study evaluated the effects of at least one type of zoledronate on skeletal-related events (SREs) or bone pain in patients with any type of metastatic bone disease; study was a placebo-controlled RCT; and study reported Brief Pain Inventory (BPI) scores at all time points examined
EXCLUSION CRITERIA: None listed
TOTAL REFERENCES RETRIEVED = 150 studies
EVALUATION METHOD AND COMMENTS ON LITERATURE USED: Two reviewers used the Jadad composite scale to score the methodologic quality of the studies for the studies that were included in the analysis
Ten of the 12 RCTs provided data on SREs. Patients receiving zoledronate had a significantly lower rate of SREs than the placebo group (RR 0.75, 95% Cl 0.69–0.81, p < 0.001). Six studies that reported BPI scores found the zoledronate group to have significantly reduced scores at three months (WMD -0.53, 95% Cl -0.72–-0.35, p < 0.001), 12 months (WMD 0.39, 95% Cl -0.62–-0.16, p < 0.001), and 24 months (WMD -0.48, 95% Cl -0.77–-0.19, p < 0.001). The incidence of pyrexia (RR 1.43, 95% Cl 1.12–1.70, p < 0.001), fatigue (RR 1.26. 95% Cl 1.11–1.43, p < 0.001), and anemia (RR 1.33. 95% Cl 1.14–1.55, p < 0.001) was higher in the zoledronate group than the placebo group for the pooled results from five to six studies.
Zoledronate was more effective in preventing SREs and bone pain than a placebo for up to 24 months in patients with metastatic bone disease. Adverse effects were a class effect related to bisphosphonates; thus, they were not specific to zoledronate. Renal effects, which are associated with this classification of drugs, were not found to be a significant adverse event among patients in these studies receiving 4 mg zoledronate in a 15-minute infusion.
A limitation was that 50% of the studies (n = 6) included in the meta-analysis received a low quality score of 2 or less. However, the authors did report that a sensitivity analysis of the pooled results was unchanged with the removal of these studies’ data from the analysis.
Nurses need to be knowledgeable about the potential adverse effects of zoledronate (more common: pyrexia, fatigue, and anemia; less common: nausea and emesis), which are the same adverse effects of other bisphosphonates. In addition, to prevent renal toxicity, the dose should not be more than 4 mg and should be delivered IV in a 100 ml solution over 15 minutes. Lastly, nurses should be aware that patients can safely receive this drug every three weeks over a period of 24 months with continued pain relief and prevention of SREs.